Table 5.
CT vs ICT | CT vs UCC | ICT vs UCC | LG vs HGa | LG vs HGb | |
---|---|---|---|---|---|
CLDN-1 IHC | ↑(0.386) | ↓(0.014) | ↓(0.001) | ↓(0.078) | ↓(0.035) |
CLDN-2 IHC | ↑(0.007) | ↑(0.489) | ↓(0.001) | ↑(0.913) | ↑(0.337) |
CLDN-4 IHC | ↑(0.039) | ↑(0.125) | ↓(0.082) | ↑(0.037) | ↑(0.011) |
CLDN-7 IHC | ↑(0.791) | ↑(0.115) | ↓(0.062) | ↓(<0.001) | ↓(0.001) |
CLDN-1 mRNA | ↓(0.624) | ↑(0.101) | ↑(0.117) | ↓(0.025) | ↓(0.017) |
CLDN-2 mRNA | ↑(0.624) | ↑(0.037) | ↑(0.727) | ↑(0.002) | ↑(0.009) |
CLDN-4 mRNA | ↓(0.624) | ↑(0.092) | ↑(0.034) | ↑(<0.001) | ↑(<0.001) |
CLDN-7 mRNA | ↑(0.047) | ↑(0.001) | ↑(0.043) | ↓(0.720) | ↓(0.819) |
Ki-67 | ↓(0.245) | ↑(0.076) | ↑(0.196) | ↑(<0.001) | ↑(<0.001) |
IHC, immunohistochemistry; CT, non-inflamed control samples; ICT, inflamed control samples; LG, low grade; HG, high grade; UCC, urothelial cell cancer. Significant changes are marked in bold; p-values are in parentheses. The Mann-Whitney U test was used to calculate statistics between two independent groups (TaT1 vs T2; LG vs HG). The non-underlined group is compared to the underlined one (reference). ↑ groups not underlined show higher expression compared with the reference group. ↓ groups not underlined show decreased expression compared with the reference group.
Including T2.
Without T2.